Zobrazeno 1 - 10
of 73
pro vyhledávání: '"S. Brugnara"'
Autor:
Carlo Renè Girardelli, Mattia Barbareschi, S. Brugnara, Elena Maria Bonandini, Mariacristina Sicher, Orazio Caffo
Publikováno v:
Drugs in Context
Drugs in Context, Vol 8, Pp 1-5 (2019)
Drugs in Context, Vol 8, Pp 1-5 (2019)
Systemic treatment for metastatic melanoma has advanced dramatically in recent years with an impressive increase in the rate of overall survival. The two main different strategies are targeted therapies (i.e. BRAF and MEK inhibitors) and immunotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5dadedbe7fdcf6058b755dbd51d35d6
https://doi.org/10.7573/dic.212582
https://doi.org/10.7573/dic.212582
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mattia Barbareschi, S. Brugnara, Carlo Renè Girardelli, Elena Maria Bonandini, Davide Donner, Mariacristina Sicher, Orazio Caffo, Franca Chierichetti
Publikováno v:
Drugs in Context, Vol 7, Pp 1-5 (2018)
Drugs in Context
Drugs in Context
Here, we report the case of a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce06ab18f66744ac81fd4909d3636b05
http://www.drugsincontext.com/treatment-combined-dabrafenib-trametinib-brafv600e-mutated-metastatic-malignant-melanoma-case-long-term-complete-response-treatment-cessation
http://www.drugsincontext.com/treatment-combined-dabrafenib-trametinib-brafv600e-mutated-metastatic-malignant-melanoma-case-long-term-complete-response-treatment-cessation
Autor:
M. Del Vecchio, S. Sava, Emilia Cocorocchio, S. De Summa, M. Maule, Sabino Strippoli, G. C.Antonini Cappellini, Marcella Occelli, Laura Ridolfi, Alice Ramondetta, Alessandro Marco Minisini, A.M. Di Giacomo, Pietro Quaglino, L. Festino, Michele Guida, S. Brugnara, V. Chiaron Sileni, Paola Queirolo, Barbara Merelli, S. Tommasi
Publikováno v:
ESMO Open
Background Checkpoint inhibitors in melanoma can lead to self-immune side-effects such as vitiligo-like depigmentation (VLD). Beyond the reported association with favorable prognosis, there are limited data regarding VLD patient features and their ec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb6745428a3061ec28447397a9bca72c
https://doi.org/10.1016/j.esmoop.2021.100064
https://doi.org/10.1016/j.esmoop.2021.100064
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
F. Valduga, S. Brugnara, M. Frisinghelli, Alessia Caldara, Mariachiara Dipasquale, Francesca Maines, V. Murgia, Antonella Ferro, Orazio Caffo, Antonello Veccia, Chiara Trentin
Publikováno v:
Anti-cancer drugs. 28(6)
To assess the activity of weekly paclitaxel (wPCT) in pretreated patients with advanced non-small-cell lung cancer (aNSCLC). In 2005, we included wPCT 80 mg/m for 6 consecutive weeks, followed by a 2-week interval in our department's everyday clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8203757a11a0985241cee0357664d1a0
https://pubmed.ncbi.nlm.nih.gov/28252532
https://pubmed.ncbi.nlm.nih.gov/28252532
Autor:
Maria Chiara di Pasquale, Alessia Caldara, Antonella Ferro, Lucianna Russo, Antonello Veccia, Enzo Galligioni, S. Brugnara, M. Frisinghelli, Orazio Caffo, Giovanni L. Pappagallo, F. Valduga, V. Murgia, B. Soini
Publikováno v:
Urology. 79:644-649
Objective To describe the feasibility and efficacy of multiple sequential rechallenges and analyze the predictive factors that may aid in selecting patients who are more likely to respond. Several studies have demonstrated the feasibility and activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d8432601488b686a03fc6a5b211d428
https://doi.org/10.1016/j.urology.2011.11.043
https://doi.org/10.1016/j.urology.2011.11.043
Autor:
Stefano Lorentini, F. Maines, Sabina Vennarini, F. Fellin, Maurizio Amichetti, S. Brugnara, Marco Schwarz, L. Widesott, Paolo Farace, Daniele Scartoni, Dante Amelio
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 99:E63-E64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be582213ce710de1298856e394aa3ae4
https://doi.org/10.1016/j.ijrobp.2017.06.741
https://doi.org/10.1016/j.ijrobp.2017.06.741
Autor:
S. Brugnara, Vanna Chiarion-Sileni, G.L. De Salvo, Jacopo Pigozzo, Michele Guida, Laura Ridolfi, P. Del Bianco, Antonella Romanini, Ruggero Ridolfi, G Colucci
Publikováno v:
British Journal of Cancer
Background: This study compared the central nervous system (CNS) metastasis incidence between a temozolomide- and a dacarbazine-based regimen in untreated stage IV melanoma patients. Methods: A total of 150 patients were randomly assigned to receive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a7b130f0ee15ef2cfeedead9a6ad033
https://doi.org/10.1038/bjc.2011.178
https://doi.org/10.1038/bjc.2011.178
Autor:
Dante Amelio, Daniele Scartoni, Paolo Farace, F. Fellin, R Pagone, L. Widesott, Marco Schwarz, Sabina Vennarini, S Brugnara, Maurizio Amichetti
Publikováno v:
Neuro-Oncology. 20:iii249-iii249
BACKGROUND: To report preliminary results of re-irradiation with proton therapy (PT) with or without chemotherapy (CHT) in difficult-to-treat recurrent glioblastoma (rGBM): patients (pts) were selected for PT because of the large tumor size or proxim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff15f9657d4bcf093655fa87da955c86
https://doi.org/10.1093/neuonc/noy139.126
https://doi.org/10.1093/neuonc/noy139.126